KLOW

What it is

KLOW has no single page in the public peptide library. The research below is the library entry for each part that does have one: kpv, ghk-cu, bpc-157, tb-500. The vials on this site are research material, not a finished drug, and they are not for human or veterinary use.

Regulatory status

Non-FDA-approved peptide sold in the wellness/gray market. No. KPV is not approved by the FDA. In July 2026 the FDA's Pharmacy Compounding Advisory Committee gave KPV a non-binding favorable vote toward the 503A compounding list. Because that vote is only a recommendation and the FDA has not completed rulemaking, KPV is not currently on the list and cannot be legally compounded on that basis. Not FDA-approved (systemic/injectable use). No, not for systemic use. Injectable or systemic GHK-Cu is not an FDA-approved drug. Copper peptides sit in the contested peptide-compounding space; the FDA advisory committee reviewed several peptides in 2026, but those recommendations are non-binding and no additions to the compounding list have been finalized, so lawful compounding remains unsettled. (Topical cosmetic use is regulated separately as a cosmetic ingredient.) Not approved by the FDA for any use. No, BPC-157 has never been approved by the FDA, or any comparable regulator, for any condition, and it has not completed the controlled human trials that approval requires. 2023: The FDA placed BPC-157 in Category 2 of its interim 503A bulk drug substances list, the category for substances that may present significant safety risks, which restricted compounding pharmacies from making it. April 2026: The FDA removed BPC-157 from that category because the nominators withdrew their nominations. BPC-157 is still not on the 503A bulks list or in Category 1. Not FDA-approved, sold in the wellness/gray market. No. TB-500 is not approved by the FDA. As neutral regulatory facts: On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend TB-5002 (free base and acetate) for the 503A compounding list, citing wound healing. But, because that vote is only a recommendation and FDA adoption is pending, TB-500 is not currently on the list and cannot be legally compounded on that basis. The same coverage of the meeting lists TB-500 among the peptides voted on and does not list full-length thymosin beta-4. In sport, it is treated as thymosin beta-4 and is prohibited at all times under the WADA list.

What the research shows

Part 1. The headline finding recorded for it: Evidence is animal and cell-based only; there are no human efficacy trials. Its anti-inflammatory basis is reviewed here. There are no controlled human trials establishing KPV for gut or skin use, so its marketed benefit is unproven in people. The anti-inflammatory rationale is supported by consistent animal and cell data, but there are no human efficacy trials, and the regulatory status is a non-binding advisory recommendation rather than approval. KPV is a tripeptide (lysine-proline-valine) corresponding to the tail end of alpha-MSH, a hormone with anti-inflammatory properties. It is discussed in wellness write-ups and research-supply channels for gut inflammation, inflammatory bowel conditions, and skin, and it is not an approved medicine. KPV retains much of alpha-MSH's anti-inflammatory activity. In laboratory models it is taken up into gut and immune cells, where it is proposed to reduce pro-inflammatory signaling, including the NF-kB pathway and downstream inflammatory messengers such as TNF-alpha. Notably, some of its anti-inflammatory activity appears independent of the MC1R receptor. These are cell and animal findings. This describes the proposed mechanism, separate from demonstrated benefit in people. Part 2. The headline finding recorded for it: For systemic use, evidence is animal and laboratory only; human data relate mostly to topical use. The systemic benefit is therefore an extrapolation from cell and animal work. Systemic efficacy rests on animal and laboratory signaling data, with no controlled human trials for the injectable wellness use. GHK-Cu is the tripeptide glycyl-L-histidyl-L-lysine bound to copper. It occurs naturally in the body and declines with age, and it is one of the most studied "copper peptides." This entry concerns the systemic, injectable wellness use for skin, hair, and tissue repair; the topical cosmetic form is cataloged separately under its ingredient name, Copper tripeptide-1. The injectable use is not an approved medicine. These are cell and animal findings. This describes the proposed mechanism, separate from demonstrated benefit from systemic use in people. Copper tripeptide-1Carrier/copper peptide Part 3. The headline finding recorded for it: Almost all done in animals rather than in humans. The research on BPC-157 is overwhelmingly preclinical. The 2025 systematic review in orthopedic sports medicine screened the literature and included 36 studies, of which 35 were preclinical (animal or laboratory) and only one involved humans. There are no completed randomized controlled human trials, and there is no long-term human data. A 2019 review reached a similar conclusion, describing consistent healing effects in rodents while noting that efficacy is “yet to be confirmed in humans.” The animal research is broad and fairly consistent, but the human research needed to draw firm conclusions has not been done. The most replicated animal findings involve tendons. In rats with a cut Achilles tendon, BPC-157 improved tendon strength, elasticity, and function and shrank the defect by day 14. The one human report is a retrospective, uncontrolled series of 12 patients with chronic knee pain. After a single knee injection, seven of them (58%) reported relief lasting more than 6 months. The report published no effect size or safety data. BPC-157, short for “Body Protection Compound-157,” is a synthetic pentadecapeptide, a chain of 15 amino acids (sequence GEPPPGKPADDAGLV). It is a lab-made fragment modeled on a larger protective protein that occurs naturally in human gastric juice, the acidic fluid the stomach uses to break down food. Unlike a hormone such as insulin, BPC-157 does not appear to act on a single, well-defined receptor. Researchers instead describe it as a “cytoprotective” agent, meaning a molecule associated with protecting and maintaining the integrity of cells and tissue in laboratory and animal models. BPC-157 has never been approved as a medicine through the FDA. The idea behind BPC-157 dates to 1975, when a Croatian medical student named Predrag Sikiric attended a lecture on the body's stress response at the University of Zagreb. He reasoned that if stress can damage the stomach, the stomach might also produce its own protective substance. By 1983, Sikiric had assembled a team that collected human and animal gastric juice from hospitals, emergency rooms, and slaughterhouses to search for the active ingredient. In 1989, the group isolated a 15 amino acid peptide called BPC-157. The name and number carried personal and patriotic meaning for Sikiric during a turbulent period in Croatia's history, as described in a 2026 STAT News profile of the researcher. From 1993, the Zagreb pharmaceutical. Part 4. The headline finding recorded for it: No human trials of the fragment; claims are extrapolated from the full-length protein. There is essentially no human evidence for the fragment. There are no completed human efficacy trials of the TB-500 fragment, and human safety data specific to it are not published. The only clinical data belong to the full-length protein, thymosin beta-4, which has been tested only in small, early trials, such as a randomized dose-escalation venous-ulcer study designed to assess safety and tolerability, and a Phase III eye-drop trial in neurotrophic keratopathy. Those results do not directly transfer to the fragment. So the marketed recovery benefit is unproven in people. There are no human efficacy or safety trials of the fragment itself; the claims rest on extrapolation from the full-length protein's preclinical work. TB-500 is a synthetic peptide sold for recovery and injury repair, commonly described as the actin-binding fragment of the natural protein thymosin beta-4 (a short piece of that larger molecule, not the full 43-amino acid protein). An important caveat is that gray-market labeling is inconsistent: material sold as "TB-500" sometimes contains the full-length protein or other fragments. It is not an approved medicine. A review of the full-length protein's regenerative biology adds the mobilization of stem and progenitor cells and less scarring, across skin, eye, heart, and brain repair models. Importantly, this is largely extrapolated from the full-length protein's animal data; the fragment itself has far less dedicated study. This describes a proposed mechanism, separate from demonstrated benefit in people.

Evidence limits

This bundle page repeats the source research for its parts. It does not give a dose, a route, or a schedule. Not medical advice. Not for human or veterinary use.

Reported actions

• Evidence is animal and cell-based only; there are no human efficacy trials
• Influence the extracellular matrix
• Deliver copper
• Act as an antioxidant and anti-inflammatory
• Support new blood-vessel formation
• Switch on gene programs linked to repair
• Almost all done in animals rather than in humans
• Binding the cell-structure protein actin
• Promoting cell migration
• Promoting blood-vessel formation
• Promoting reduced inflammation